MicroRNA-326 suppresses the proliferation, migration and invasion of cervical cancer cells by targeting ELK1

Zhang,Ping; Kong,Feng; Deng,Xinchao; Yu,Yunhai; Hou,Congzhe; Liang,Tingting; Zhu,Lin

doi:10.3892/ol.2017.5852

MicroRNA-326 suppresses the proliferation, migration and invasion of cervical cancer cells by targeting ELK1

Authors:
- Ping Zhang
- Feng Kong
- Xinchao Deng
- Yunhai Yu
- Congzhe Hou
- Tingting Liang
- Lin Zhu
View Affiliations

Affiliations: Department of Gynecology, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China, Central Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China
Published online on: March 13, 2017 https://doi.org/10.3892/ol.2017.5852
Pages: 2949-2956
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although microRNAs (miRNAs or miRs) are able to function as oncogenes or tumor suppressors, the role of miR-326 in regulating human cervical cancer cells remains unclear. In the present study, the expression of miR‑326 was identified to be downregulated in cervical cancer cell lines and primary tumor samples, and the overexpression of miR‑326 decreased cell proliferation, migration and invasion in cervical cell lines. Bioinformatics prediction and experimental validation results revealed that the function of miR‑326 was achieved by targeting and repressing ETS domain-containing protein Elk‑1 (ELK1) expression. ELK1 was targeted directly by miR‑326, which was downregulated in human cervical cancer tissues compared with that in adjacent normal tissues. The results of the present study suggest that miR‑326, a potential tumor suppressor, may be used in the treatment of cervical cancer.

View Figures

View References

1	Catarino R, Petignat P, Dongui G and Vassilakos P: Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol. 6:281–290. 2015. View Article : Google Scholar : PubMed/NCBI
2	Pimple S, Mishra G and Shastri S: Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol. 28:4–10. 2016. View Article : Google Scholar : PubMed/NCBI
3	Morris E and Roett MA: Genital cancers in women: Cervical cancer. FP Essent. 438:18–23. 2015.PubMed/NCBI
4	Karlidag T, Cobanoglu B, Keles E, Alpay HC, Ozercan I, Kaygusuz I, Yalcin S and Sakallioglu O: Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol. 28:31–36. 2007. View Article : Google Scholar : PubMed/NCBI
5	Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
6	Noordhuis MG, Eijsink JJ, Roossink F, de Graeff P, Pras E, Schuuring E, Wisman GB, de Bock GH and van der Zee AG: Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: A systematic review. Int J Radiat Oncol Biol Phys. 79:325–334. 2011. View Article : Google Scholar : PubMed/NCBI
7	Davis-Dusenbery BN and Hata A: Mechanisms of control of microRNA biogenesis. J Biochem. 148:381–392. 2010.PubMed/NCBI
8	Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
11	Juan L, Tong HL, Zhang P, Guo G, Wang Z, Wen X, Dong Z and Tian YP: Identification and characterization of novel serum microRNA candidates from deep sequencing in cervical cancer patients. Sci Rep. 4:62772014. View Article : Google Scholar : PubMed/NCBI
12	Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar : PubMed/NCBI
13	Zeng K, Zheng W, Mo X, Liu F, Li M, Liu Z, Zhang W and Hu X: Dysregulated microRNAs involved in the progression of cervical neoplasm. Arch Gynecol Obstet. 292:905–913. 2015. View Article : Google Scholar : PubMed/NCBI
14	Sdel Díaz-González M, Deas J, Benítez-Boijseauneau O, Gómez-Cerón C, Bermúdez-Morales VH, Rodríguez-Dorantes M, Pérez-Plasencia C and Peralta-Zaragoza O: Utility of microRNAs and siRNAs in Cervical Carcinogenesis. Biomed Res Int. 2015:3749242015.PubMed/NCBI
15	Wang L, Wang B, Fang M, Guo F and Cui M: Identification of microRNAs and target genes involved in serous ovarian carcinoma and their influence on survival. Eur J Gynaecol Oncol. 35:655–661. 2014.PubMed/NCBI
16	Tarasov VA, Matishov DG, Shin EF, Boiko NV, Timoshkina NN, Makhotkin MA, Lomonosov AM, Kirpii AA, Kit OI and Maksimov AY: Coordinated aberrant expression of miRNAs in colon cancer. Genetika. 50:1232–1244. 2014.(In Russian). PubMed/NCBI
17	Serpico D, Molino L and Di Cosimo S: microRNAs in breast cancer development and treatment. Cancer Treat Rev. 40:595–604. 2014. View Article : Google Scholar : PubMed/NCBI
18	Mo W, Tong C, Zhang Y and Lu H: microRNAs' differential regulations mediate the progress of human papillomavirus (HPV)-induced cervical intraepithelial neoplasia (CIN). BMC Syst Biol. 9:42015. View Article : Google Scholar : PubMed/NCBI
19	Kim J, Krichevsky A, Grad Y, Hayes GD, Kosik KS, Church GM and Ruvkun G: Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci USA. 101:360–365. 2004. View Article : Google Scholar : PubMed/NCBI
20	Thatcher EJ, Flynt AS, Li N, Patton JR and Patton JG: MiRNA expression analysis during normal zebrafish development and following inhibition of the Hedgehog and Notch signaling pathways. Dev Dyn. 236:2172–2180. 2007. View Article : Google Scholar : PubMed/NCBI
21	Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
22	Zhang ZL, Bai ZH, Wang XB, Bai L, Miao F and Pei HH: miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells. PLoS One. 10:e01188142015. View Article : Google Scholar : PubMed/NCBI
23	Wang S, Lu S, Geng S, Ma S, Liang Z and Jiao B: Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma. Med Oncol. 30:3732013. View Article : Google Scholar : PubMed/NCBI
24	Zhou J, Xu T, Yan Y, Qin R, Wang H, Zhang X, Huang Y, Wang Y, Lu Y, Fu D and Chen J: MicroRNA-326 functions as a tumor suppressor in glioma by targeting the Nin one binding protein (NOB1). PLoS One. 8:e684692013. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta (CT)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Janicek MF and Averette HE: Cervical cancer: Prevention, diagnosis, and therapeutics. CA Cancer J Clin. 51:92–118. 2001. View Article : Google Scholar : PubMed/NCBI
27	Magné N, Deutsch E and Haie-Meder C: Current data on radiochemotherapy and potential of targeted therapies for cervical cancers. Cancer Radiother. 12:31–36. 2008. View Article : Google Scholar : PubMed/NCBI
28	Iorio MV and Croce CM: microRNA involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012. View Article : Google Scholar : PubMed/NCBI
29	Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
30	Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M, Paganelli A, Di Marcotullio L, Caffaelli E, Screpanti I, et al: Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 27:2616–2627. 2008. View Article : Google Scholar : PubMed/NCBI
31	Wu H, Wang Y, Wu C, Yang P, Li H and Li Z: Resveratrol induces cancer cell apoptosis through miR-326/PKM2-mediated ER stress and mitochondrial fission. J Agric Food Chem. 64:9356–9367. 2016. View Article : Google Scholar : PubMed/NCBI
32	Wang R, Chen X, Xu T, Xia R, Han L, Chen W, De W and Shu Y: MiR-326 regulates cell proliferation and migration in lung cancer by targeting phox2a and is regulated by HOTAIR. Am J Cancer Res. 6:173–186. 2016.PubMed/NCBI
33	Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, Schmittgen T, Jiang J, diPierro CG, Li Y, Chiocca EA, et al: The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci. 29:15161–15168. 2009. View Article : Google Scholar : PubMed/NCBI
34	Zhou J, Xu T, Yan Y, Qin R, Wang H, Zhang X, Huang Y, Wang Y, Lu Y, Fu D and Chen J: MicroRNA-326 functions as a tumor suppressor in glioma by targeting the Nin one binding protein (NOB1). PLoS One. 8:e684692013. View Article : Google Scholar : PubMed/NCBI
35	Galamb Á, Benczik M, Zinner B, Vígh E, Baghy K, Jeney C, Kiss A, Lendvai G and Sobel G: Dysregulation of microRNA expression in human cervical preneoplastic and neoplastic lesions. Pathol Oncol Res. 21:503–508. 2015. View Article : Google Scholar : PubMed/NCBI
36	Hollenhorst PC, McIntosh LP and Graves BJ: Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem. 80:437–471. 2011. View Article : Google Scholar : PubMed/NCBI
37	Martinelli E, Morgillo F, Troiani T and Ciardiello F: Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treat Rev. 53:61–69. 2016. View Article : Google Scholar : PubMed/NCBI
38	O'Donnell A, Odrowaz Z and Sharrocks AD: Immediate-early gene activation by the MAPK pathways: What do and don't we know? Biochem Soc Trans. 40:58–66. 2012. View Article : Google Scholar : PubMed/NCBI
39	Odrowaz Z and Sharrocks AD: ELK1 uses different DNA binding modes to regulate functionally distinct classes of target genes. PLoS Genet. 8:e10026942012. View Article : Google Scholar : PubMed/NCBI
40	Pallai R, Bhaskar A, Sodi V and Rice LM: Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription. 3:323–335. 2012. View Article : Google Scholar : PubMed/NCBI